Gastric Antral Vascular Ectasia in Patients With Cirrhosis: Risk-factors and Associations.
NCT ID: NCT05690750
Last Updated: 2023-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2023-01-19
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Endoscopic Treatment Effect Based on HVPG
NCT06863519
The Natural History and Prognostic Factors of Compensated Cirrhosis.
NCT03144700
Optimal Clinical Predictors to AKI in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage
NCT04184934
A Randomized Controlled Trial to Assess the Role of Emergent vs Early Endoscopy in Child B and C Cirrhotic Patients With Acute Variceal Bleed (AVB)-EARLY - AVB
NCT06785701
Non-invasive Method for Predicting the Presence of Gastroesophageal Varices in Patients With Cirrhosis
NCT04123509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\- Secondary objectives:
1. Relationship of etiology of cirrhosis with occurrence of GAVE.
2. Relationship of severity of cirrhosis (CTP score and MELD score), with GAVE.
3. Features of metabolic syndrome among cirrhotic patients with GAVE.
4. Variceal grade and previous endotherapy with occurrence of GAVE among patients with cirrhosis.
5. Prevalence of proximal gastric vascular ectasias among cirrhotic patients with GAVE.
(b) Methodology:
* Study population:
All out-patients and in-patients who undergo upper gastrointestinal endoscopy (EGD) in the Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), will be evaluated for inclusion. Diagnosis of cirrhosis will be based on a combination of imaging features, liver biopsy, elastography measurements, and signs of portal hypertension.
We will include patients with cirrhosis with age \>18-years, who have characteristic findings of GAVE on endoscopy in this study.
\- Study design:
Case-control, observational study.
* Study period:
3-months.
* Sample size with justification:
There are three existing studies which have shown an association of diabetes mellitus (DM) with occurrence of GAVE \[Fouad M. JGH Open 2021; Smith E. Am J Med 2016; Cleach AL. Canadian Liver Journal 2019\]. The prevalence of DM among patients with and without GAVE ranged from 50%-64%, and 24.2% to 29.3%, respectively, in these three studies.
Assuming a prevalence of DM of 50% among cirrhosis patients with GAVE, and 25% prevalence of DM among cirrhotic patients without GAVE, we will need 44 cases (and 88 controls) to detect a difference with power of 80% and significance level of 0.05, using the test of independent proportions. We plan to include 50 cases and 100 controls in this study.
\- Intervention: None.
\- Monitoring and assessment: Not applicable.
* Statistical Analysis:
Patients with GAVE will be matched in a 1:2 ratio to controls without GAVE, based on age (±5 years), gender, and timing of diagnostic EGD (±1 year). Comparisons will be performed using Chi-square tests or Fisher exact tests for categorical variables, and t tests, Wilcoxon rank-sum tests or signed rank tests for continuous variables as appropriate.
Univariate and multivariate, case and control matched conditional logistic regression models will be utilized to evaluate potential associations between specific risk factors and the diagnosis of GAVE. A p≤0.05 decision rule is established a priori as the null hypothesis rejection rule for all comparisons.
\- Adverse effects:
No intervention planned, hence no adverse effects anticipated.
\- Stopping rule of study:
Not applicable.
(c) Expected outcome of the project:
Elucidation of the predictors of GAVE in patients with cirrhosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case
Cirrhosis with GAVE
No intervention
No intervention as this is an observational study.
Control
Cirrhosis without GAVE
No intervention
No intervention as this is an observational study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention as this is an observational study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Patients unable or unwilling to give informed consent.
3. Endoscopic treatment of GAVE in past one month.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Liver and Biliary Sciences, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ILBS-Cirrhosis-54
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.